These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25807876)

  • 21. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral changes causing chronic hepatitis C.
    Cockey CD
    AWHONN Lifelines; 2000; 4(4):20-1. PubMed ID: 11898280
    [No Abstract]   [Full Text] [Related]  

  • 24. Liver Fibrosis in the Post-HCV Era.
    Pinzani M
    Semin Liver Dis; 2015 May; 35(2):157-65. PubMed ID: 25974901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early decrease of liver stiffness after initiation of antiviral therapy in patients with chronic hepatitis C.
    Moser S; Gutic E; Schleicher M; Gschwantler M
    Dig Liver Dis; 2016 Aug; 48(8):970-1. PubMed ID: 27260330
    [No Abstract]   [Full Text] [Related]  

  • 26. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
    Blanco JR; Rivero-Juárez A
    Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.
    Iacobellis A; Andriulli A
    Expert Opin Pharmacother; 2009 Aug; 10(12):1929-38. PubMed ID: 19563272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010.
    Brook G; Main J; Nelson M; Bhagani S; Wilkins E; Leen C; Fisher M; Gilleece Y; Gilson R; Freedman A; Kulasegaram R; Agarwal K; Sabin C; Deacon-Adams C;
    HIV Med; 2010 Jan; 11(1):1-30. PubMed ID: 20059574
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?
    Navasa M; Forns X
    J Hepatol; 2007 Feb; 46(2):185-8. PubMed ID: 17161494
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chronic hepatitis. 2: Treatment].
    Blum HE; Moradpour D
    Dtsch Med Wochenschr; 2001 Jul; 126(27):786-9; quiz 790-2. PubMed ID: 11486479
    [No Abstract]   [Full Text] [Related]  

  • 31. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Shouval D
    J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
    [No Abstract]   [Full Text] [Related]  

  • 32. EVALUATION OF ANTIVIRAL THERAPY TREATMENT FOR LIVER CIRRHOSIS CAUSED BY CHRONIC HEPATITIS C AND HEPATITIS C BY 31P-MRS, BASED ON METABOLITE DETECTION.
    Gu JS; Sun RR; Shen S; Yu ZJ
    J Biol Regul Homeost Agents; 2015; 29(2):443-50. PubMed ID: 26122235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspects of care for the hepatitis C positive patient.
    Wodak A
    Aust Fam Physician; 1998 Sep; 27(9):787-90. PubMed ID: 9769525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic hepatitis C: practical aspects.
    Schalm SW; Brouwer JT
    Acta Gastroenterol Belg; 1997; 60(3):204-10. PubMed ID: 9396176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fibrosis in chronic hepatitis C infection: mechanisms and cofactors].
    Bedossa P
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B163-7. PubMed ID: 12180284
    [No Abstract]   [Full Text] [Related]  

  • 36. [Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
    Sugawara Y; Makuuchi M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):605-9. PubMed ID: 15359869
    [No Abstract]   [Full Text] [Related]  

  • 37. The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?
    Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2012 Jul; 57(1):226-8; author reply 229. PubMed ID: 22390901
    [No Abstract]   [Full Text] [Related]  

  • 38. PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
    Morisco F; Amoruso D; Stroffolini T; Caporaso N
    Dig Liver Dis; 2008 May; 40(5):391-2. PubMed ID: 18291731
    [No Abstract]   [Full Text] [Related]  

  • 39. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Koretz RL; Gluud C
    N Engl J Med; 2009 Mar; 360(11):1151; author reply 1152-3. PubMed ID: 19279350
    [No Abstract]   [Full Text] [Related]  

  • 40. Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
    Biliotti E; Palazzo D; Serani M; Silvestri AM; Volpicelli L; Esvan R; Franchi C; Spaziante M; Sorrentino F; Taliani G
    Ann Hematol; 2017 Jun; 96(6):1043-1045. PubMed ID: 28378040
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.